Inhibitor compounds hepatitis c.

A racemate, diastereoisomer or optical isomer of a compound of formula (I): wherein B is (1-10C) alkyl, (C3-7) cycloalkyl, or (C1-4) alkyl- (C3-7), a) wherein said alkyl, cycloalkyl and alkyl-cycloalkyl may be mono-, di- or trisubstituted by (C1-3) alkyl; b) wherein said alkyl, cycloalkyl and alkyl-cycloalkyl may be mono- or disubstituted selected from hydroxy and O- (1-4C) alkyl substituents; c) wherein each of said alkyl groups may be mono-, di- or trisubstituted by halogen; d) wherein each of said cycloalkyl having 4, 5, 6 or 7 members, optionally having one (for the 4-, 5, 6 or 7-membered) or two (for the 5-, 6- or 7 members) -CH2- groups not directly linked to each other replaced by -O- such that the O-atom is linked to the group X by at least two carbon atoms; X is O or NH; R3 is alkyl (C2-8), (C3-7) alkyl or (C1-3) alkyl- (C3-7), wherein said alkyl, cycloalkyl and alkyl-cycloalkyl may be mono-, di- or trisubstituted by (1-4C) alkyl; L0 is H, halogen, (1-4C) alkyl, -OH, -O-alkyl (1-4C), -NH2, -NH (C1-4) or -N ((C1-4) alkyl) 2; L1, L2 are each independently halogen, cyano, (1-4C) alkyl, -O- (1-4C) alkyl, -S-alkyl (1-4C), -SO- (C1-4) alkyl, or - SO2-alkyl (1-4C), wherein each of said alkyl is optionally substituted with one to three halogen atoms; and L1 or L2 (but not both at the same time) can be H; or L0 and L1 or L0 and L2 may be covalently bonded to form, together with the two carbon atoms to which they are attached, a carbocyclic ring of 5 or 6 members, where one or two -CH 2 groups which are not directly linked together, can be replaced by -O- each independently or NRa wherein Ra is H or alkyl (1-4C), and wherein said carbo or heterocyclic ring is optionally mono- or disubstituted with (C1 4); R2 is R20, -NR22COR20, -NR22COOR20 -NR22R21 and -NR22CONR21R23, wherein R20 is selected from (C1-8alkyl), (C3-7) and (C1-4) alkyl- (C3-7), wherein said cycloalkyl and alkyl-cycloalkyl may be mono-, di- or trisubstituted by (C1-3) alkyl; R21 is H or R20 as defined above, R22 and R23 are independently selected from H and methyl, R1 is ethyl or vinyl; RC is hydroxy or NHSO2RS wherein RS is (1-6C) alkyl, (C3-7) alkyl, (C1-6) alkyl- (C3-7), phenyl, naphthyl, pyridinyl, (1-4C) -phenyl, (1-4C) alkyl or naphthyl (C1-4) -pyridinyl; each of which is optionally mono-, di- or trisubstituted with substituents selected from halogen, hydroxy, cyano, (1-4C) alkyl, O- (C1-6) alkyl, -CO-NH2, -CO--NHalkyl (C1- 4) -CO-N ((1-4C) alkyl) 2, -NH2, -NH (C1-4) and -N ((C1-4) alkyl) 2, in which (1-4C) alkyl and O-alkyl (C1-6) are optionally substituted with one to three halogen atoms; and each of which is optionally monosubstituted with nitro; oRS is -N (RN2) (RN1), wherein RN1 and in RN2 are independently selected from H, (1-6C) alkyl, (C3-7) alkyl, (C1-6) alkyl- (C3-7) , aryl and (C1-6) alkylaryl; wherein said alkyl (C1-6), (C3-7) alkyl, (C1-6) alkyl- (C3-7) alkyl and aryl (C1-6alkyl) aryl are optionally substituted with one or more substituents independently selected from halogen, alkyl (1-6C), hydroxy, cyano, O- (C1-6) alkyl, -NH2, -NH (1-4C) alkyl, -N ((C1-4) alkyl) 2, -CO -NH2, -NHalkyl -CO- (C1-4), -CO-N ((1-4C) alkyl) 2, -COOH, and -COO-alkyl (1-6C); or RN2 and RN1 are linked, together with the nitrogen to which they are attached to form a saturated monocyclic heterocycle or unsaturated 3 to 7 members, or a saturated bicyclic heterocycle or unsaturated 9- or 10 members, each of which optionally contains one to three additional heteroatoms independently selected from N, S and O, and each of which is optionally substituted with one or more substituents independently selected from halogeno, (1-6C) alkyl, hydroxy, cyano, O-alkyl (C1 -6), -NH2, -NH (1-4C) alkyl, -N ((C1-4) alkyl) 2, -CO-NH2, -CO--NHalkyl (C1-4), -CO-N ((C1 -4)) 2, -COOH, and -COO-alkyl (1-6C); or a pharmaceutically acceptable salts or esters.